Using clinical trials to assess long-term drug safety is problematic; in Australia, simple data linkage based on Medicare numbers may provide useful monitoring information
The era of pharmaceutical medicines began with the synthesis of acetylsalicylic acid (ASA) in the late 19th century. The reason for its synthesis was that natural salicylic acid was irritating to gastric mucosa, and the synthesised product less so. Subsequently, more potent non-steroidal anti-inflammatory drugs (NSAIDs) were introduced and, more recently, cyclooxygenase-2 (COX-2) inhibitors, also with a lesser risk of gastric irritation and bleeding. 1 The rapidly widespread and often prolonged use of these agents meant that even a small increase in the risk of a serious adverse event could be very significant in population health terms.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 University of Tasmania, Hobart, TAS.
- 2 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.
- 1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
- 2. Bresalier RS, Sandler RS, Hui Quan, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoa050493 (accessed Feb 2005).
- 3. US Food and Drug Administration. Center for Drug Evaluation and Research. FDA Alert for Practitioners on Celebrex (celecoxib). FDA ALERT 12/17/04. Available at: www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.htm (accessed Jan 2005).
- 4. US Food and Drug Administration. Center for Drug Evaluation and Research. Naproxen information. Available at: www.fda.gov/cder/drug/infopage/naproxen/default.htm (accessed Jan 2005).
- 5. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoa050405 (accessed Feb 2005).
- 6. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoa050330 (accessed Feb 2005).
- 7. Mukherjee D, Nissen S, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
- 8. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
- 9. Nelson M, McNeil J, Reid C, Krum H. Factors influencing family physician adherence to hypertension treatment guidelines recommendations on the initiation of pharmacotherapy. Questionnaire survey. Am J Cardiovasc Drugs 2003; 3: 437-441.
- 10. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406-412.
- 11. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Writing Group for the Women’s Health initiative Investigators. JAMA 2002; 288: 321-333.
- 12. Graham DJ, Campen D, Cheetham C, et al. Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2004; 13: S287-S288.
- 13. Nelson RC, Palsulich B, Gogolak V. Good pharmacovigilance practices: technology enabled. Drug Saf 2002; 25: 407-414.